Heres what they found: In the diabetes group: 17 out of 194 patients taking semaglutide developed NAION ( 8.9% ) 6 out of 516 patients taking non-semaglutide drugs developed NAION ( 1.8% ) In the overweight or obese group: 20 out of 361 patients taking semaglutide developed NAION ( 6.7% ) 3 out of 618 patients taking non-semaglutide drugs developed NAION ( 0.8% ) We can see from these numbers that more people who were taking semaglutide developed this eye condition, compared with those who were taking different medications
34 , 18751891.e7 (2022)
Ozempic, which contains the active ingredient semaglutide, is a brand-name medication approved by the Food and Drug Administration (FDA) to manage blood glucose levels in people with Type 2 diabetes
MOTS-C and Retatrutide fill a particular niche metabolic optimization during aggressive fat loss and they fill it exceptionally well
The GLP-1 drugs are the latest class to show a benefit in patients, this time with OSA, but like other tools have nontrivial side effects, cost concerns, and patient persistence issues that balance out the headline benefits. The size of the underlying patient populations, which are expected to surpass 1.3 billion globally by 2050, as well as the under penetration of CPAP treatment, which Andrew ballparks at 15% or less in many markets, reinforces the analysts argument